# Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

> **NCT06381154** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 25 (estimated)

## Conditions studied

- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Adenocarcinoma
- Stage II Pancreatic Cancer AJCC v8
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Unresectable Pancreatic Adenocarcinoma

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Endoscopic Ultrasound
- **DRUG:** Fluorouracil
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin
- **PROCEDURE:** Lymph Node Biopsy
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Oxaliplatin
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Photodynamic Therapy
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Questionnaire Administration
- **DRUG:** Verteporfin

## Key facts

- **NCT ID:** NCT06381154
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-06
- **Primary completion:** 2029-12-06
- **Final completion:** 2029-12-06
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06381154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06381154, "Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06381154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*